Table V.

Multivariable-adjusted odds of statin utilization by race and ethnicity among persons with HIV with likely indications for statins

	Model 1	P value	Model 2	P value	Model 3	P value	Model 4	P value	Model 5	P value	Model 6	P value
Black (vs white)	0.52 (0.41, 0.66)	<.01	0.56 (0.44, 0.73)	<.01	0.57 (0.44, 0.74)	<.01	0.51 (0.38, 0.66)	<.01	0.54 (0.39, 0.74)	<.01	0.59 (0.42, 0.85	.004
Hispanic (vs white)	0.57 (0.40, 0.83)	<.01	0.70 (0.48, 1.03)	.07	0.73 (0.49, 1.09)	.12	0.67 (0.45, 1.01)	.06	0.60 (0.37, 0.97)	.04	0.60 (0.36, 1.02)	.06
Age			1.06 (1.05, 1.08)	<.01	1.06 (1.05, 1.08)	<.01	1.05 (1.04, 1.07)	<.01	1.06 (1.04, 1.08)	<.01	1.06 (1.04, 1.08)	<.001
Female sex			0.85 (0.62, 1.19)	.35	0.85 (0.60, 1.12)	.35	0.84 (0.60, 1.19)	.33	0.94 (0.63, 1.40)	.90	0.91 (0.59, 1.42)	.69
Private insurance					1.02 (0.36, 2.86)	.97	0.98 (0.35, 2.77)	.97	1.15 (0.36, 3.72)	.81	1.90 (0.44, 8.17)	.39
Medicare					0.96 (0.54, 1.69)	.88	0.87 (0.49, 1.55)	.64	0.97 (0.49, 1.91)	.92	0.79 (0.38, 1.64)	.53
Medicaid or other public aid					0.93 (0.54, 1.59)	.78	0.93 (0.54, 1.60)	.79	0.97 (0.51, 1.84)	.92	0.83 (0.42, 1.64)	.59
HTN							1.63 (1.21, 2.20)	<.01	1.51 (1.06, 2.15)	.02	1.44 (0.97, 2.13)	.07
DM							1.35 (1.02, 1.79)	<.01	1.53 (1.10, 2.13)	.01	1.99 (1.36, 2.91)	<.001
CHD							0.99 (0.76, 1.29)	.94	1.36 (0.99, 1.87)	.06	1.87 (1.30, 2.69)	.001
Nadir CD4 (per 100 cells/mm3 higher)									1.20 (1.12, 1.29)	<.01	1.14 (1.04, 1.24)	.003
Log10 of peak viral load									0.99 (0.94, 1.04)	.56	0.98 (0.93, 1.04)	.61
ART use									8.84 (3.53, 22.1)	<.01	8.56 (2.72, 26.9)	<.01
Protease inhibitor–based ART									1.36 (0.98, 1.86)	.06	1.31 (0.92, 1.86)	.13
Baseline LDL (per 10 mg/dL higher)											1.11 (1.06, 1.15)	<.001